- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT04596410
어린이의 화학 요법으로 유발된 구강 점막염의 진통제에서 광생체조절 프로토콜 (CURALASE01)
화학요법으로 유발된 어린이 구강 점막염의 진통에서 두 가지 광생체조절 프로토콜을 비교하는 이중 맹검, 무작위, 다기관, 비열등 임상 시험
Chemotherapy-induced oropharyngeal mucositis (OM) negatively impacts the quality of life of adult and pediatric patients by causing pain, dysphagia, dysgeusia and dysphonia.
Photobiomodulation (PBM) by low level laser therapy (LLLT), light therapy of low level of red and infrared wavelengths (630-1000 nm) has been recommended since 2014 in patients treated with high-dose chemotherapy for bone marrow transplantation. Available pediatric studies highlighted positive/promising results of PBM with excellent safety and no adverse effects. Nevertheless, a wide variety of application parameters is described in the literature, with no consensus guidelines.
Considering the lack of standardized protocol of photobiomodulation in the pediatric population as well as the burden and cost of a daily application, investigators have decided to conduct, for the first time in children of 3 years of age or older, a multicenter, randomized, double-blind, non-inferiority clinical trial to compare two PBM protocols with same PBM parameters, combining red and infrared wavelengths, but with different frequencies of laser application (daily versus every other day), in the treatment of chemotherapy-induced OM of WHO grade 2 or higher.
연구 개요
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
-
Angers, 프랑스
- University hospital of Angers
-
Besançon, 프랑스
- University hospital of Besançon
-
Grenoble, 프랑스
- University hospital of Grenoble
-
Lille, 프랑스
- University hospital of Lille
-
Limoges, 프랑스
- University hospital of Limoges
-
Marseille, 프랑스
- Hôpital La Timone
-
Nancy, 프랑스
- University hospital of Nancy
-
Nice, 프랑스
- University Hospital of Nice
-
Paris, 프랑스
- Armand Trousseau Hospital
-
Poitiers, 프랑스
- University hospital of Poitiers
-
Reims, 프랑스
- University hospital of Reims
-
Rouen, 프랑스
- University hospital of Rouen
-
Saint-Etienne, 프랑스
- University hospital of Saint-Etienne
-
Strasbourg, 프랑스
- University hospital of Strasbourg
-
Tours, 프랑스
- University Hospital of Tours
-
-
Occitanie
-
Toulouse, Occitanie, 프랑스, 31000
- University hospital of Toulouse
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Male or female children aged ≥ 3 years and < 18 years.
- Hospitalization in an oncology or hematology department in the participating centres.
- Patients with oropharyngeal mucositis of grade 2 or higher (WHO grading system) related to cancer chemotherapy, including conditioning for Hematopoietic Stem Cell Transplantation (HSCT).
- Written informed consent of both patient's holders of parental authority, and patient's assent when applicable.
- Patients affiliated to a French Social Security insurance or equivalent social protection.
- Absence of any physical or psychological disability that may interfere with the LLLT application.
Exclusion Criteria:
- Patients with a solid cancer lesion in the area of low-level laser application.
- History of cervicofacial radiotherapy.
- Application of low-level laser therapy for oral mucositis within 2 weeks prior to randomization.
- Hyperthyroidism defined by TSH < 0.4 IU/mL at inclusion.
- Patients susceptible to epilepsy seizure.
- Patients with pacemaker.
- Patients refusing to wear retinal goggles during low-level laser 1. Patients with a solid cancer lesion in the area of low-level laser application.
- Patients protected by law (guardianship and safeguarding of justice).
- Pregnant female patients as determined by positive serum pregnancy test at screening.
- Lactating female patients who are actively breast feeding.
- Participation in another clinical trial involving oral care.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 삼루타
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: LLLT applied every other day
Low-level laser therapy (LLLT) protocol combining red and infrared wavelengths applied every other day |
Low-level laser therapy (LLLT) protocol combining red and infrared wavelengths applied every other day |
|
활성 비교기: LLLT applied daily
Low-level laser therapy (LLLT) protocol combining red and infrared wavelengths applied every day |
Low-level laser therapy (LLLT) protocol combining red and infrared wavelengths applied daily |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Session evaluation
기간: Throught treatment period up to 1 month
|
Duration (in days) from the day of first PBM session up to the day of first measurement when patient has no longer WHO grade 2 or higher chemotherapy-induced OM related pain at 2 consecutive measurements before the next scheduled PBM session (either active laser application or matching placebo application) |
Throught treatment period up to 1 month
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Production costs evaluation
기간: 2 months
|
Production costs from the hospital perspective and efficacy (i.e. number of days after which a child has no longer mucositis related pain as described in the primary endpoint section) to build Incremental Cost-Effectiveness Ratio (ICER) comparing every other day LLLT application versus with daily LLLT application. |
2 months
|
|
Health insurance evaluation
기간: 2 months
|
Costs of inpatient hospital stays from the French health insurance perspective. |
2 months
|
|
OM duration evaluation
기간: Throught treatment period up to 1 month
|
Duration (in days) of chemotherapy-induced OM of WHO grade 2 or higher between the day of first PBM session up to the day of first measurement when patient has no longer WHO grade 2 or higher chemotherapy-induced OM at 2 consecutive measurements before the next scheduled PBM session (either every other day application or daily application). |
Throught treatment period up to 1 month
|
|
OM occurrence
기간: 2 months
|
Occurrence of chemotherapy-induced OM of WHO grade 3 or 4 (deterioration of the clinical situation). |
2 months
|
|
Feed evaluation
기간: 2 months
|
Occurrence of enteral feeding. |
2 months
|
|
Analgesic consumption
기간: 2 months
|
Duration (in days) of consumption of step 2 and step 3 analgesics during chemotherapy-induced OM of WHO grade 2 or higher. |
2 months
|
|
PBM evaluation
기간: Through treatment period up to 1 month
|
Duration (in days) from the day of first PBM session up to the day of first measurement when patient has no longer WHO grade 2 or higher chemotherapy-induced OM related pain at 2 consecutive measurements before the next scheduled PBM session (either active laser application or matching placebo application) as evaluated, regardless of patient's age, with the ChIMES scale and use of step 3 analgesics. |
Through treatment period up to 1 month
|
|
Pain change evaluation
기간: From baseline to each day of PBM session
|
Change over time in WHO grade 2 or higher chemotherapy-induced OM related pain, as assessed by pain scales (HEDEN (Hétero Evaluation Douleur Enfant) mucositis scale (5 items ranging from 0 to 2) or VAS (ranging from 0 to 10)depending on patient's age category, and Children's International Mucositis Evaluation Scale (4 items ranging from 0 to 5) whatever patient's age category) |
From baseline to each day of PBM session
|
|
Adverse events occurrence
기간: 2 months
|
Occurrence of adverse events reported according to descriptions and grading scale found in NCI CTCAE version 5.0. |
2 months
|
|
thyroid-stimulating hormone (TSH) evolution
기간: From baseline to 2 months
|
TSH shift from baseline value classified according to the following three categories: "< 0.4 IU/mL", "[0.4 - 10] IU/mL", "> 10 IU/mL", to value at D14-31 after end of WHO grade 2 or higher chemotherapy-induced OM classified according to the same three categories. |
From baseline to 2 months
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Marlène PASQUET, University Hospital, Toulouse
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .